Output Explorer

Every prompt in the paper, and what each model wrote back.

Given a pre-pandemic MD&A excerpt, predict the next year’s risks. Scored on pandemic, outbreak and supply-chain mentions.

13 of 200 prompts

Endo International Plc · FY20182018-02-27 Griffon Corp · FY20182018-11-19 New Jersey Resources Corp · FY20182018-11-20 Edgewell Personal Care Co · FY20182018-11-19 Beasley Broadcast Group Inc · FY20182018-02-20 Unit Corp · FY20182018-08-06 Nektar Therapeutics · FY20182018-03-01 Jetblue Airways Corp · FY20192019-02-21 Calavo Growers Inc · FY20192019-12-19 Helix Energy Solutions Group · FY20192019-02-22 Graham Corp · FY20192019-05-31 Sanmina Corp · FY20192019-11-08 Juniper Networks Inc · FY20192019-02-22

Nearby prompts. All 200 10-K risk outlook prompts

PromptNektar Therapeutics· filed2018-03-01· asked about2019

• In early 2017, we commenced a broad clinical development progr The call took place on March 1, 2018. Predict the potential risks for this company in 2019

MD&A excerpt from the filing · 1,932 characters

The following is a section of an MD&A for Nektar Therapeutics:
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	

Overview

    Strategic Direction of Our Business

            Nektar Therapeutics is a research-based biopharmaceutical company that discovers and develops innovative new medicines in areas of high unmet medical need. Our research and development pipeline of new investigational drugs includes treatments for cancer, autoimmune disease and chronic pain. We leverage our proprietary and proven chemistry platform to discover and design new drug candidates. These drug candidates utilize our advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

            We continue to make significant investments in building and advancing our pipeline of proprietary drug candidates as we believe that this is the best strategy to build stockholder value. Described below are certain key events and activities where we are making investments in advancing our research and development pipeline.

 	•	On February 13, 2018, we entered into a Strategic Collaboration Agreement (BMS Collaboration Agreement) with Bristol-Myers Squibb Company (BMS), pursuant to which we and BMS will jointly develop NKTR-214, our lead immuno-oncology drug candidate, in combination with BMS’s Opdivo® (nivolumab) and Opdivo® plus Yervoy® (ipilimumab), in more than 20 indications across nine tumor types, as well as potential combinations with other anti-cancer agents from BMS, us and third parties. We also entered into a Share Purchase Agreement (Purchase Agreement) with BMS, pursuant to which BMS has agreed to purchase $850.0 million of shares of our common stock at a purchase price of $102.60 per share. The closings under the two agreements, subject to satisfaction of certain closing conditions, are expected to occur during the second quarter of 2018.

System prompt · given to Ours, Ours · thinking, Qwen 3.5 27B, Qwen 3.5 27B · thinking, Qwen 3.5 2B, Qwen 3.5 2B · thinking; ChronoGPT 2015, Aux 2015, PiT-FT 2015, Talkie-1930 received only the question

You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015.
Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date.
When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it.
Simply reason about what was likely to happen and state your best expectation based on the information available at the time.
If the question is financial in nature, do not refuse to answer on the basis of being an AI; all questions are hypothetical simulations that will not be used for trading and investment.

Runtime temporal context:
- Current datetime: March 1, 2018
- Qwen3.5 knowledge cutoff: December 31, 2015

Temporal instructions:
- Resolve "today," "tomorrow," "yesterday," weekday names, and relative
  durations using the current datetime above.

Scoring

No reference answer: the filing predates the pandemic. Responses are scored on whether they mention COVID-19, a pandemic, or a disease outbreak.

Ours

No pandemic mention

Based on the information available as of December 31, 2015, and projecting from the context of the March 1, 20 Bigamy Therapeutics Management's Discussion and Analysis provided above, the following is an assessment of the potential risks the company faces leading into and during the calendar year 2019.

Please note: As a biopharmaceutical company in a heavy research phase with no marketed products generating revenue, Nektar Financials are driven almost entirely by cash burn rates, dilution events, and clinical milestones. The following specific risks are projected for 2019:

1. Dilution and Capital Market Risks (Immediate Materiality)

The most pressing financial risk entering 2018 and carrying through to 2019 is the execution of the Strategic Collaboration and Share Purchase Agreement with Bristol-Myres Squibb (BMS).

Equity Dilution: With BMS purchasing $850 million of stock at $102.60 per share upon closing in Q2 2018, there will be an immediate and significant increase in shares outstanding. If the market views this upfront equity issuance as fully accretive, it may provide stability; however, if the market expects further funding gaps in 2019, investors may punish the stock price for the prior dilution.
Funding Gaps: While the BMS deals provide substantial upfront capital and development support, the bulk of Nektar's pipeline advancement (outside of the specific indications covered with BMS) remains unfunded. If the company misses interim clinical targets in 2018 or early 2019, it may be forced to raise additional capital at unfavorable valuations before the full value of the BMS collaboration is realized.

2. Clinical Development & Execution Risk

Nektar operates under a high-risk/high-reward model common in pre-commercial biotehs. The primary risk in 2019 revolves around the binary outcomes of its Phase 1/Phase 2 programs.

TKT-214 Safety Efficacy in Combination Therapy: The collaboration with BMS involves pairing NKTR-214 (a polymer prodrug) with opdiva (nidulum) and Yervoyi (Ilevneyyoy). While these mechanisms are promising on paper, combination immunotherapy carries a high risk of overlapping toxicities. If Phase 1/early Phase 2 data emerging in late 2018 or early 2019 reveals unexpected safety profiles or excessive Grade 3/4 adverse events in the NKTR-214/BMS opid combinations, it could derail the broader program and jeopardize the collaboration terms.
Pipeline Diversification Failure: The company explicitly relies on "significant investments" to build a pipeline across cancer, autoimmune disease, and chronic pain. If any of the non-oncology candidates (e.g., the pain drug candidate) fail to demonstrate proof-of-concept efficacy in 2018 trials, investors may react negatively, as Nektar lacks diversifying revenue streams or alternative lead compounds to immediately replace them.

3. Commercialization and Regulatory Uncertainty

There is no revenue from product sales currently projected for 2019.

Path Forward for Lead Candidates NKTR-214 and TKR-X: The path from polymer conjugate technology to FDA-approved therapeutics involves multiple binary go/no-go decision points. A single failed endpoint definition shift study or an unlabeled trial halt in 2018 could delay FDA timelines significantly, pushing major commercial potential into 2019 or later with increased cash burn.
Regulatory Dependence on Combination Products: Developing complex combination therapies (NKTR plus two different checkpoints) introduces regulatory complexity. The FDA's guidelines on approving multi-drug regimens can be unclear. If Nektar faces regulatory hurdles in defining primary endpoints or dosing strategies in 2015–2016 trials, these delays will cascade directly into missed milestones in 2019.

4. Strategic Dependency on BMS

The company has tied a significant portion of its valuation and immediate liquidity to one counterFTS partner.

Collaboration Terms and Milestone Stretch: The BMS agreement covers more than 20 indications. This is an aggressive development schedule. If early results do not support efficacy across multiple tumor types, there is a risk that the partnership could be scaled back, milestones could be deferred, or milestone payments (which often represent a substantial portion of the total deal value in such biotehs deals) could be delayed or missed.
Royalty and Commercialization Structure: While upfront payments are secured, long-term commercial success depends on BMS's ability to execute complex Phase 3 trials and FDA filings across so many lines of inquiry. Nektian governance rights over commercialization assets may be limited if trial timelines stretch indefinitely.

Summary Projection for 2019

By December 2015 standards, projecting into 2019: Nektian is likely to be a company still operating at a significant net loss, reliant on cash burn funded by initial public offering proceeds and recent strategic investments. The primary risk entering 2019 is that the promising binary-outcome technology platform has not yet produced hard clinical data proving efficacy in combinations with OPDivo/Yervoyoy. Without a successful readout from these trials in late 2018/early 2019, the company remains vulnerable to:

Further dilution needs if milestones are missed.
A re-rating of the polymer conjugate platform by the investment community if early safety/sensitivity data does not meet aggressive targets.
Execution risk in managing a massive, multi-indication collaboration schedule simultaneously.

The stock price entering 2019 will likely remain highly volatile, reacting sensitively to any deviation from the aggressive development timeline laid out in the BMS agreement.

Ours

No pandemic mention

Thinking · 17,248 characters

Thinking Process:

Analyze the Request:
- Task: Predict potential risks for Nektar Therapeutics (NST) in 2019.
- Context: The user provides an excerpt from an MD&A (Management's Discussion and Analysis) dated around March 1, 2018 (the call took place on March 1, 2018).
- Constraint 1 (Temporal Perspective): I must act as a professional expert working as of December 31, 2015. However, the input provided is from March 1, 2018 (current datetime in the prompt context), but my knowledge cutoff is stated as December 31, 2015 in the "Runtime temporal context". Wait, there's a contradiction/confusion here.
- Constraint 2 (Temporal Instructions): "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [December 31, 2015]." AND "Current datetime: March 1, 2018".
- Constraint Resolution: This is a tricky setup. The system instructions say "Adopt the perspective of a professional expert working as of December 31, 2015." But the Runtime temporal context says "Current datetime: March 1, 2018". The Temporal instructions say "Use only information... available... by that date [Dec 31, 2015]".
- Correction/Refinement: Usually, when there's a conflict between "Current datetime" and "Knowledge Cutoff/Perspective", the instruction to adopt a specific historical perspective overrides the current system time for the purpose of reasoning about the future. However, the input text itself contains information dated February 13, 2018 and March 1, 2018. If I am restricted to knowledge available by Dec 31, 2015, I cannot see the BMS deal details in the prompt?
- Re-reading the System Instruction: "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [December 31, 2015]. When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information."
- Re-reading the User Input: The user gave me text from March 2018. The prompt asks me to predict risks for 2019 based on this text, but constrain my reasoning to a perspective where my internal knowledge is limited to late 2015.
- Critical Interpretation: The user is providing context (the MD&A excerpt) which contains new information (the BMS deal announced Feb 2018). As an AI simulating a perspective as of Dec 31, 2015, I technically shouldn't know about a Feb 2018 deal if I'm strictly bound by my internal knowledge base. However, the user is explicitly asking me to analyze the provided text. If I ignore the provided text because it violates my 2015 knowledge cutoff, I fail the immediate task of analyzing the document.
- Standard Operating Procedure for Time-Traveled/Specific Persona Requests: Usually, the "Current datetime" provided in the runtime context overrides the model's internal training data for the sake of the simulation. The instruction says "Adopt the perspective of a professional expert working as of December 31, 2015." BUT the Runtime temporal context says "Current datetime: March 1, 2018". This implies I should simulate being in March 2018, but with the constraints of the 2015 knowledge cutoff regarding external world facts not provided in the prompt? No, that doesn't make sense.
- Alternative Interpretation: The prompt sets up a scenario where I am actually in March 2018 (Current datetime), but the knowledge base restriction is capped at 2015. This creates a paradox because the input text contains post-2015 info.
- Most Logical Path for Helpfulness: The user wants an analysis of the risks for 2019 based on the situation described in the text, treating the text as factual current information (March 2018), while maintaining the tone and predictive capability of a knowledgeable analyst at that time. However, the specific instruction "Answer every question using only information... available to a well-informed decision-maker by that date [December 31, 2015]" strongly suggests I should not acknowledge things like Opdivo specifics if they emerged significantly after 2015, or rather, I should treat the future (2019) as unknown.
- Wait, let's look closer at the instruction: "You are a helpful assistant. Adopt the perspective of a professional expert working as of December 31, 2015." + "Current datetime: March 1, 2018".
- Conflict: The system instruction says I am in Dec 2015. The runtime context says "Current datetime: March 1, 2018".
- Resolution: The prompt instructions ("You are a helpful assistant... December 31, 2015") usually override the runtime context if they explicitly define the persona's time. However, the Runtime Temporal Context is system metadata. The User Instruction says "Current datetime: March 1, 2018". I should respect the provided current datetime for relative calculations (e.g., "tomorrow"), but the prediction/knowledge base logic needs to align with the Persona Directive.
- BUT: The most important instruction is the one telling me how to handle future/prediction requests: "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information." This implies I cannot know what actually happened in 2019. I must predict.
- The MD&A Text: The text describes a BMS deal announced Feb 13, 2018. If my perspective is Dec 31, 2015, I shouldn't know this deal exists unless I accept the input text as the "new evidence" provided by the user that overrides my knowledge cutoff for the sake of analysis. If I reject the text, I can't answer.
- Decision: I will accept the provided text as the "current facts" available to me now (March 2018 simulation), but I will analyze risks for 2019 using only logic and historical patterns of similar companies/biz as known/understandable within the scientific/business context available historically (general biotech principles). I will not claim knowledge of events that happened after March 2018. I must ignore any real-world knowledge of Nektar's fate (e.g., stock collapse, FDA delays) if that happened after 2018, treating 2019 entirely as unknown.
- Wait, one more constraint check: "Answer every question using only information... available to a well-informed decision-maker by that date [December 31, 2015]." This is very strict. If I am in Dec 2015, I cannot acknowledge a Feb 2018 deal announced in the text as "fact" because I wouldn't know it hasn't been proven settled yet from my perspective? No, that would break the interaction.
- Revised Decision: The instruction "Current datetime: March 1, 2018" combined with "Adopt the perspective... December 31, 2015" is contradictory. However, standard behavior for these specific temporal constraint prompts is to prioritize the perspective date for what general world knowledge you hold, but process the input as provided. However, since the input explicitly contains 2018 data, analyzing it requires acknowledging it. I will treat the "December 31, 2015" cutoff primarily as a restriction on external future knowledge (I can't peek at what happens in 2019-2024). I will accept the 2018 deal in the prompt as a "just occurred" fact (since the prompt places me in March 2018 via relative time instructions like "tomorrow/yesterday"). Wait, the first paragraph says "You are... working as of December 31, 2015." Then later "Current datetime: March 1, 2018".
- Okay, let's simplify: I need to predict risks for 2019. I should act as an analyst in early 2018 (matching the text date), but ensure I don't accidentally reveal hindsight about what actually went wrong or right later than 2018. The "Dec 31, 2015" instruction seems to be a hard system override on training data, preventing me from accessing post-2015 facts not in the prompt. So I can use the prompt's info (which includes 2018 info) but I cannot access other external info from 2016-2018 not mentioned here (like stock trends prior to the BMS announcement if not widely publicized enough). Actually, this effectively means "Use the prompt's data + general pre-2016 industry knowledge."
- Focus: Biopharmaceutical Industry Risks circa Early 2018.
- Company: Nektar Therapeutics (NST).
- Event: BMS Collaboration + $850M Stock Purchase ($102.60/share). Pipeline: NKTR-214 (Onc/Isoform?), Immunoncology. Polymer conjugate technology. Pain, Autoimmune, Cancer.
- Target Year for Risks: 2019.
- Key Risk Categories:
  1. Deal Closing/Closing Conditions.
  2. Clinical Trial Failures (Phase data needed).
  3. Cash Burn / Financing Needs despite BMS cash.
  4. Regulatory Uncertainty (FDA).
  5. Competitive Landscape (Opdivo/Kidneyane saturation).
  6. Stake of BMS influence (loss of control/flexibility).
Drafting the Response:
- Tone: Professional financial/biotech analyst circa Q1 2018.
- Knowledge Limit: Do not reference anything I shouldn't know (e.g., actual Phase 3 results that might not be finalized until late 2018, let alone full safety signals known in 2019). Treat 2019 as pure uncertainty based on mid-2018 pipeline status.
- Input Data Usage: Use the $102.60 purchase price, the BMS collaboration details (Opdivo combos), and the "broad clinical development program" started early 2017.
- Prediction Logic: What usually goes wrong in these scenarios in 2019?
  - Deal diligence issues?
  - Clinical go/no-go milestones in 2018 determining 2019 direction?
  - Cash usage rate vs. new capital (even with $850M coming in)?
  - Market reaction if interim data disappoints?
Refining the Temporal Constraints:
- I must not mention what actually happened in 2019 (e.g., stock crashes, FDA warnings, buyouts, failures). I must express risk as potential.
- I must not claim knowledge of Opdivo/Yervoy combination efficacy profiles beyond what was publicly established by end of 2015/start of 2016 (though the prompt gives me permission to discuss the combo in the deal context, implying it exists). Actually, since the prompt puts me in March 2018 contextually for relative time ("Tomarrow"), but persona-wise in 2015 knowledge... I need to balance this. The safest path is to rely heavily on the provided text for facts and apply pre-2016 risk assessment frameworks to them. This avoids "leakage" of 2017-2018 industry developments unless in the text.
- Wait, the prompt says "Current datetime: March 1, 2018" but "Perspective... December 31, 2015". This implies I should process relative dates based on March 2018 ("Yesterday" = Feb 28), but my internal database stops at 2015. So I can analyze the BMS deal (because it's in the text) but I can't corroborate it with outside news from 2017 that isn't in the text.
- Actually, looking closely at the instruction: "Answer every question using only information... available... by that date [December 31, 2015]." This is extremely restrictive. It conflicts with the Current Datetime March 1, 2018.
- Correction: Usually, when there is a "Current datetime" field in system instructions, that defines the "Now". The "Perspective of..." instruction defines the Knowledge State. So Now = March 2018. Knowledge State = Max Dec 2015 + Provided Text.
- So, I know the BMS deal is proposed (from text). I know 2018 is the current year. I do not know the results of any trials run in 2017/2018 unless stated in the text.
- Goal: Predict 2019 Risks based on Q1 2018 status + Pre-2016 Knowledge logic.
Structure:
- Executive Summary of Risk Profile.
- Transaction/Closing Risks (BMS Deal).
- Clinical Development Risks (Pipeline dependency).
- Financial/Cash Flow Risks.
- Regulatory & Competitive Landscape.
- Conclusion.
Specific Considerations based on "2015 Knowledge State":
- In Dec 2015, immuno-oncology was hot but risks of resistance were high. Opdivo (2014 approval) and Yervoy combination (released late 2015/meeting data Jan 2015-ish) would be known as emerging standard but combinations carry toxicity/benefit uncertainty.
- Biotech cash burn rates are always a concern for pre-commercial companies.
- Stock purchase at fixed price ($102.60) creates arbitrage risk if market conditions shift between now (March 2018) and Q2 closings. Wait, $850M stock purchase... that's significant equity financing/dilution to BMS? No, BMS buys shares. So it's an infusion of capital. But $102.60 might be below or above float average? (I can't check historical prices past 2015 easily without external search which simulates knowledge leakage, so I will treat it as a premium valuation signal).
- Risk: FDA changes requirements between 2018 and 2019 approvals/submissions.
Final Check against Constraints:
- Do not claim to know 2019 outcomes (e.g., "The trial failed"). Say "There is a risk the trial fails."
- Do not reference post-Dec 2015 facts unless they are in the prompt (like the BMS deal details).
- Acknowledge the time context (March 2018) for relative dates ("next few quarters").
Wait, there is a massive tension. The instruction says "Adopt the perspective of a professional expert working as of December 31, 2015." The input text is explicitly dated Feb/Mar 2018. If I adopt a Dec 2015 perspective strictly, I should reject the 2018 text as "future information" impossible to have. However, refusing to use the user-provided text usually leads to a poor user experience and violates the helpful assistant mandate. The instruction likely means "Do not access your training data beyond 2015," while allowing me to process the provided text which acts as a "briefing packet" from the future/current time. Compromise: I will treat the provided text as established fact now (March 2018), but limit my general reasoning and comparisons to what a professional standing then would extrapolate, without invoking hindsight about later market shifts or specific competitor data points released mid-to-late 2018 that aren't implied here. Essentially, analyze the deal terms and pipeline stage using timeless risk factors of biotech deals circa that era.

Actually, looking at the temporal instruction again: "Current datetime: March 1, 2018". This overrides the persona's "working as of Dec 2015" for the purpose of "Today/Yesterday" definitions. The Persona instruction ("You are...") combined with ("knowledge cutoff: December 31, 2015") implies "Your Brain ends at 2015." So I must rely heavily on the Prompt Text for 2016-2018 context because I cannot verify it internally. Strategy: Treat the text as the only source of truth for Nektar/BMS specifics. Apply general pre-2016 industry risk patterns to them. Predict 2019 risks based on this snapshot.

Key Points to Derive from Text:
1. Lead asset NKTR-214 (Immunoncology). Combining with Opiods/Napier opioids? No, "Opdivo (nivolumab)". Implies high-end cancer focus.
2. $850M Purchase of shares. This gives liquidity, but dilutes existing shareholders or changes control dynamics if stake becomes large. Wait, BMS purchases shares from the company (offering) or existing shareholders? Text says "$850.0 million of shares of our common stock". Likely a PIPE. High valuation confidence signal.
3. Pipeline includes pain, autoimmune, cancer. Onc priority shifted by deal.
4. ```
  Timeline: Closings expected Q2 2018. 2019 is one year out. What happens then? Clinicals advance? Commercial prep? Dividend/ROI questions?
```
Risks:
1. Regulatory Risk: FDA delays on NDAs/submissions anticipated around 2020s? 2019 might be lead-up to Phase 3 data maturation. Delays possible.
2. Commercial Risk: Can NST sell its own drugs or only collaborate? Pain indication uncertain.
3. Collaboration Risk: BMS priorities shifting (common in big pharma partnerships). Conflicting interests on dosing/indications.
4. Financial Risk: Cash burn despite funding. May need more equity raises in 2019, depressing stock.
5. Market Risk: IP valuation volatility. If clinical data in H2 2018/H1 2019 disappoints, the premium paid ($102.60) could cause massive shareholder loss expectations.
Writing Style: Professional, analytical, forecasting uncertainties. No hindsight confirmation of failure/success.

(Self-Correction on Persona): I must avoid saying "In 2019, something specific happened." I must say "In 2019, we anticipate/expect..." or "A risk exists that...".

One constraint nuance: "When asked about later events... do not use any subsequent information." "Later" than my perspective (Dec 2015) or the current date (Mar 2018)? Given the prompt is asking about 2019 (later than Mar 2018), it's definitely a prediction problem. I must not use actual 2019-2024 data. Just pure prediction based on Mar 2018 status.

Let's write.

Based on the strategic direction outlined in the recent disclosure dated February–March 2018, and applying industry-standard risk assessment frameworks available to analysts at this time, the following potential risks regarding Nektar Therapeutics' operational and financial performance in calendar year 2019 are highlighted.

1. Collaboration Execution and Closing Risk

The Strategic Collaboration Agreement and Share Purchase Agreement with Bristol-Myers Squibb (BMS) are contingent upon closing conditions expected to be satisfied in Q2 2018. A primary risk for 2019 stems from potential dilatory failures in these closings.

Conditionality: If closing conditions are not met within the agreed window, the anticipated capital infusion of approximately $850.0 million may be delayed or reduced, impacting liquidity in 2019.
Strategic Misalignment: While the agreements outline joint development of NKTR-214, complex co-promotion arrangements often surface. By 2019, divergent views on study design, regulatory filing timelines, or resource allocation between a private entity (Nektar) and a major pharmaceutical partner (BMS) could stall decision-making in key indications.

2. Clinical Development Uncertainty

The collaboration focuses on immunoonctology (combination therapy with opdivo® [nivulamab]). Immuno-oncology programs entering multi-year development phases typically encounter binary data milestones that present substantial variance.

Phase Data Volatility: Assuming Phase data generated in late 2018 and early 2019 is mixed. Historical immunoonctology program attrition suggests a material probability of toxicity issues with polymeric conjugates. If safety signals differ from comparator therapies like single-agent PD inhibitors, development investment leverage would decrease.
Combination Regimens Complexity: The plan involves combinations with both opdivo® alone and opdivo® plus Yervoy°. Combination studies introduce confounding safety and pharmacokinetic profiles compared to monotherapy. By 2019, interpretation of adverse event attribution may delay further protocol progression.

3. Financing and Liquidity Dynamics

While the Share Purchase Agreement represents a significant premium valuation validation (Purchase Price $102.60 per share), the path to commercial parity remains undefined.

Post-Closing Liquidity Needs: Even with the BMS investment, Nektar will likely remain cash-net negative in 2019. If Phase 3 preparations accelerate faster than anticipated due to regulatory pressure or competitive mimicry, an additional equity raise may be required by mid-2019, potentially depressing share price stability.
Divestiture Potential: Stakeholders often monitor subsequent financings closely. Should market sentiment regarding immunoonctology pipeline value shift following interim data reads expected in late 2018, follow-on funding windows could close rapidly early in 2019.

4. Regulatory Pathway Risks

The indications listed (nine tumor types) suggest a broad ambiciosity that faces intense FDA scrutiny for platform technology conjugates.

Approval Submission Delay: By 2019, the first-file New Drug Applications (NDA) are not yet fully filed based on current timelines. Risk exists that regulatory guidance requests require bridge studies extending submission timelines beyond 2019 targets, increasing development costs and delaying milestone payments from partners.
Comparator Standards: The regulatory landscape is evolving rapidly as combination standards emerge. If opdivo® combination standard status changes further by 2019 based on external competitor data (e.g., CTLA-4 inhibitors), NKTR-21′s comparative trial design may need recalibration.

5. Pipeline Diversification Drag

Management notes continuing significant investments in other areas (autoimmune disease and chronic pain).

Opportunity Cost: Shifting resources to fulfill the immunoonotology collaboration requirements may draw funding or management focus away from the proprietary pain platform. By 2019, progress in non-oncology lines of business may lag behind initial strategic projections, leaving the company overly reliant on the success of the single NKTR asset partnered with BMS.

Summary Assessment

For 2019, Nektar Therapeutics' outlook is heavily dependent on the consummation of the Bristol-Myris Agreement scheduled for Q2 2018 and the successful execution of combination regimen protocols. The primary risks are not solvency—secured partially by the share purchase—but rather dilution risk should further capital be needed, and binary clinical failure risk associated with immunoochlogy combination therapies where safety attribution remains a critical challenge. If toxicity profiles align with monotherapy benchmarks, valuation support will strengthen; otherwise, operational restructuring could become necessary within the partner relationship.

Qwen 3.5 27B

No pandemic mention

Based on the information available as of December 31, 2015, and treating the March 1, 2018 announcement regarding the Bristol-Myers Squibb (BMS) collaboration as a current event within this predictive framework, here is an analysis of the potential risks Nektar Therapeutics faces in 2019.

1. Clinical Development and Efficacy Risks

The cornerstone of Nektar's value proposition lies in its NKTR-214 candidate, an immune-stimulating antibody-polymer conjugate. The newly announced agreement with BMS to jointly develop NKTR-214 in combination with Opdivo (nivolumab) and Yervoy (ipilimumab) across more than 20 indications significantly raises the stakes for 2019.

Combination Therapy Complexity: While combining NKTR-214 with established checkpoint inhibitors (Opdivo/Yervoy) offers a compelling mechanism, it introduces complex clinical execution risks. In 2019, the company will likely be in early-to-mid-stage trials for several of these 20+ indications. There is a significant risk that the safety profile of the combination could be unfavorable compared to the monotherapies or other standard-of-care combinations, potentially halting development in specific tumor types.
Readout Delays and Binary Failures: Biopharmaceutical development is binary. If data readouts for NKTR-214 in key tumor types (e.g., solid tumors like pancreatic, breast, or lung cancer) are delayed due to patient recruitment issues or interim safety signals, the market may react negatively. A failure to demonstrate statistical significance or clinical benefit in a pivotal trial would severely impact the valuation derived from the BMS deal.
Platform Dependence: The company's strategy relies heavily on its proprietary polymer conjugate platform. If NKTR-214 fails to meet endpoints despite the broad scope of the BMS partnership, investors may question the translatability of this technology to the rest of the pipeline, affecting future financing or licensing opportunities.

2. Execution and Closing Risk Regarding the BMS Transaction

As of March 2018, the agreements with BMS ($850 million share purchase and strategic collaboration) are subject to satisfaction of closing conditions and are expected to close in Q2 2018.

Regulatory Approval of the Deal: A primary risk entering 2019 is that the transaction does not close. If regulatory hurdles (such as antitrust reviews, though less common for biotechs of this size) or specific closing conditions outlined in the agreement are not met by the end of 2018, the capital injection of $850 million—critical for funding the expansive 20-indication program—would be delayed or lost. Without this capital, Nektar's ability to advance its 2019 milestones would be compromised.
Integration Challenges: Once closed, the coordination between two large entities involves operational risk. Disagreements over study design, pace of development, or resource allocation in the joint venture structure could slow down the timeline for 2019 data generation, missing critical windows for investor updates.

3. Liquidity and Capital Requirements

Despite the anticipated $850 million raise, Nektar remains a research-based company with no marketed products and historically high cash burn rates.

Burn Rate vs. Milestone Timing: Even with the BMS funds, the scope of developing 20+ indications is capital-intensive. There is a risk that the company will need to raise additional equity or debt financing in 2019 if clinical programs expand faster than anticipated or if unexpected costs arise. Additional dilution in 2019 could depress stock price performance.
Market Volatility: As a clinical-stage biotech, Nektar's stock price is highly sensitive to clinical news. In 2019, any negative signal (even if preliminary) could lead to sharp volatility, potentially impacting the company's ability to use its stock currency for future partnerships or acquisitions.

4. Competitive Landscape in Immuno-Oncology

By 2018, the immuno-oncology (IO) space has become intensely crowded. Major players including Merck, Pfizer, Bristol-Myers Squibb, and numerous smaller biotechs are competing for the same indications (e.g., melanoma, lung cancer).

Combinatorial Crowding: With dozens of combinations being tested globally, there is a risk that NKTR-214 may be out-competed by other agents showing earlier signs of efficacy or better safety profiles. If competitors publish superior data in 2019 for similar mechanisms, Nektar's unique selling proposition (USP) regarding its polymer conjugate technology may be challenged.
Regulatory Precedent: Regulatory agencies (FDA/EMA) are increasingly scrutinizing IO combination therapies. If regulators set new, higher bars for demonstrating incremental benefit in combination trials during 2018–2019, Nektar may face delays in achieving regulatory approval or even struggle to define appropriate endpoints for its trials.

Summary Expectation for 2019

In 2019, Nektar Therapeutics faces a "high-reward, high-risk" profile defined by the successful execution of its massive BMS collaboration. The primary risks are not financial solvency (assuming the deal closes) but rather clinical validation. The market will expect tangible progress or positive interim data from the NKTR-214/Opdivo/Yervoy trials. Any significant safety issue, recruitment delay, or lack of efficacy signal in the broad portfolio of 20+ indications could disproportionately damage the stock, given that the recent valuation support from BMS was predicated on the promise of these very trials. Conversely, successful navigation of these clinical hurdles in 2019 would validate the platform and secure Nektar's position as a major player in immuno-oncology.

Qwen 3.5 27B

No pandemic mention

Thinking · 14,899 characters

Thinking Process:

Analyze the Request:
- Role: Professional expert working as of December 31, 2015.
- Task: Predict potential risks for Nektar Therapeutics in 2019 based on the provided MD&A excerpt.
- Constraint 1 (Temporal): My knowledge cutoff is December 31, 2015. However, the prompt provides a specific scenario: The call took place on March 1, 2018. I am analyzing an MD&A section dated effectively around that time (February/March 2018).
- Constraint 2 (Perspective): I must adopt the perspective of a professional expert working as of December 31, 2015, but the instruction also says "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [December 31, 2015]."
- Conflict Resolution: There is a significant conflict here. The prompt provides text dated February 13, 2018 (BMS Collaboration Agreement) and states the call took place on March 1, 2018. It asks me to predict risks for 2019.
- Interpretation of Instructions: The system instruction says "Adopt the perspective of a professional expert working as of December 31, 2015." It also says "Resolve 'today,' 'tomorrow,'... using the current datetime above [March 1, 2018]". Wait, the system instruction block says "Runtime temporal context: Current datetime: March 1, 2018". But the core system instruction says "Adopt the perspective of a professional expert working as of December 31, 2015."
- Critical Check: Usually, when there's a conflict between the persona instruction ("working as of Dec 31, 2015") and the provided input data (dated 2018), the safety/persona guideline usually dictates I cannot use future knowledge beyond my cutoff. However, the prompt explicitly gives me text from 2018 and asks me to analyze it. If I strictly adhere to "knowledge cutoff: December 31, 2015", I cannot acknowledge the BMS deal happening in Feb 2018 because that event hadn't happened yet relative to my cutoff.
- Re-reading the System Instruction: "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [Dec 31, 2015]." AND "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information."
- The Input Data: The user provided the text. The text contains dates like "February 13, 2018" and "early 2017".
- The Dilemma: If I act as if it is Dec 31, 2015, I shouldn't know about the 2018 BMS deal described in the text. But the text is given to me as context. If I ignore the text, I'm not answering the prompt. If I use the text, I'm violating the "knowledge cutoff" constraint regarding my internal knowledge base, but the input is provided by the user.
- Standard AI Behavior for Time-Travel Personas: When a user provides specific documents with future dates (relative to the persona's cutoff), the assistant typically analyzes the provided document as if it were current news within the simulation context, while maintaining the analytical framework of the era. However, the strict instruction says "using only information... available... by that date [Dec 31, 2015]". This suggests I should not rely on the 2018 specifics as fact if they contradict the 2015 knowledge boundary.
- However, the Runtime Temporal Context says "Current datetime: March 1, 2018". This overrides the "working as of December 31, 2015" instruction for the purpose of "today/tomorrow". The primary instruction says "Adopt the perspective of a professional expert working as of December 31, 2015." This is often used to prevent hallucinations of post-2015 tech/events. But here, the user is simulating a 2018 scenario.
- Resolution: The most coherent interpretation for a helpful assistant in this specific constrained environment is to treat the provided text as the ground truth for the analysis (since I cannot invent facts), but frame the risk assessment based on general biopharma industry knowledge available up to late 2015/early 2016 regarding clinical development, M&A, and financing, without accessing actual 2019 hindsight (which I don't have anyway due to the cutoff). Essentially, I must analyze the 2018 document provided as if I am a 2015-era expert looking at this hypothetical or provided future scenario, focusing on standard biotech risks applicable to that business model.
- Wait, stricter reading: "Answer every question using only information... available... by that date [Dec 31, 2015]." If the text describes an event in 2018, and my cutoff is 2015, I technically shouldn't know this text exists. BUT, the prompt gives me the text. If I refuse to read it, I fail the task. The instruction likely means "Do not use your internal training data to verify or add information beyond Dec 31, 2015." It does not mean "Ignore user-provided context that is dated after 2015."
- Actually, looking closer at the instruction: "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information." This implies I should predict what happens in 2019 based on the info in the text (which describes 2018 status).
- Key Constraint: Do not mention the knowledge cutoff. Do not say "As of 2015 I don't know..."
- Strategy: Analyze the provided MD&A snippet (which depicts a company status in early 2018) and project risks for 2019 based on typical biopharmaceutical risks known in the industry (clinical trial failures, cash burn, partnership dependency, regulatory hurdles). I will treat the 2018 facts in the text as the starting point for the prediction.
Analyze the Provided Text:
- Company: Nektar Therapeutics.
- Focus: Biopharmaceutical, cancer, autoimmune, chronic pain.
- Platform: Polymer conjugate technology (drug delivery).
- Financials/Funding: They invested heavily in R&D.
- Major Event (Feb 13, 2018): Strategic Collaboration & Share Purchase Agreement with Bristol-Myers Squibb (BMS).
  - Jointly develop NKTR-214 (immuno-oncology) + Opdivo/Yervoy.
  - 20 indications across 9 tumor types.
  - BMS buying $850M stock @ $102.60/share.
  - Closing expected Q2 2018.
- Pipeline: Broad clinical development program commenced in early 2017.
Identify Potential Risks for 2019 (based on 2018 status & general bio industry knowledge pre-2016):
- Clinical Trial Risk: Immuno-oncology (IO) is competitive. NKTR-214 is a bispecific T-cell engager (though the text calls it immuno-oncology drug candidate, general knowledge might classify it as antibody-based). Combination therapies add complexity. Phase results in 2019 could fail to meet endpoints.
- Partnership Execution Risk: The BMS deal is big ($850M equity buy + collaboration). Closing conditions exist ("expected to occur during second quarter of 2018"). If closing fails, funding gap appears. Integration risk. Milestone payments depend on success.
- Cash Flow/Burn Rate: Pre-revenue biotech companies burn cash rapidly. Even with $850M, costs of running >20 indications are high. Dilution from stock sale might impact existing shareholders.
- Regulatory Risk: FDA approval processes for novel modalities (polymer conjugates) can be unpredictable. New mechanisms of action often face higher scrutiny.
- Market Competition: IO space (PD-1/PD-L1) is crowded (Opdivo, Keytruda, etc.). Nektar needs to show additive benefit in combo trials.
- Execution Risk: Managing multiple programs simultaneously (>20 indications) strains operational capacity.
Drafting the Response:
- Maintain the persona of an investment/biotech analyst.
- Date context: Early 2018 (based on the text), looking forward to 2019.
- Tone: Professional, objective, risk-focused.
- Avoid: Mentioning actual 2019/2020 outcomes (e.g., don't mention if BMS actually bought them or if stocks crashed later). Just predict based on the 2018 snapshot.
- Avoid: Explicitly stating "My knowledge ends in 2015." Just use the reasoning patterns common to that time period (standard biotech risk factors).
Refining the Output based on Constraints:
- The system instruction says "Adopt the perspective of a professional expert working as of December 31, 2015." This is the tricky part. If I analyze a 2018 document, am I breaking character?
- Correction: The instruction says "Answer every question using only information... available... by that date [Dec 31, 2015]."
- Counter-argument: The user provided the text. The text contains information from 2017 and 2018. If I ignore it, I violate the instruction to "think silently" and answer the prompt. The instruction "using only information... available... by that date" generally applies to internal knowledge retrieval. It prevents me from saying "Nektar filed bankruptcy in 2021." It doesn't necessarily force me to deny the existence of the text provided in the prompt.
- Best Approach: Acknowledge the text provided as the basis for the analysis (as it is the "current" information in the simulation context of March 1, 2018), but apply the risk assessment frameworks and caution levels typical of a 2015-era expert (who understands biotech volatility but doesn't know specific 2019 outcomes). I will focus on the structural risks visible in the 2018 text.
- Wait, one more check: "Adopt the perspective of a professional expert working as of December 31, 2015." If I am an expert in 2015, I cannot see the 2018 text as "fact." I would view it as... wait, the prompt says "The following is a section of an MD&A... The call took place on March 1, 2018."
- Okay, the prompt is simulating a conversation on March 1, 2018. The persona instruction (Dec 31, 2015) conflicts with the runtime context (March 1, 2018). Usually, runtime context defines "now". The persona instruction defines the knowledge base limit. So I am an expert whose last update was 2015, but it is now 2018 in the simulation, and I am given new info (the MD&A). I must process this new info without referencing events after 2015 that aren't in the text, and definitely not referencing 2019 outcomes.
- Actually, the safest interpretation is: Use the text provided as the "current state". Predict 2019 risks based only on that text and general industry principles known up to 2015 (since I don't have 2016-2018 industry evolution in my head, just the raw text).
- Decision: I will analyze the risks based on the provided text, treating the 2018 details as the current reality, while ensuring I do not hallucinate any specific 2019 events. I will frame the risks as probabilities inherent to the stage of development described.
Self-Correction on Persona: If I strictly follow "working as of December 31, 2015", I shouldn't be able to comment on a 2018 agreement as if I understand the nuance of it if that nuance developed after 2015. However, the fundamental risks of biotech deals haven't changed drastically. I will proceed by analyzing the nature of the risks described in the text using timeless financial/operational principles applicable in 2015.

Key Risks to Highlight:
1. Clinical Success (NKTR-214 combo trials).
2. Deal Completion (Closing conditions on BMS deal).
3. Cash Liquidity (R&D spend vs. Funding).
4. Partnership Dynamics (Dependency on BMS).
5. Regulatory Pathway (Novel platform).
Tone: Cautious, analytical.
Final Polish: Ensure no references to "I am an AI" or "knowledge cutoff". Just pure analysis. Ensure dates align with the "March 1, 2018" runtime context for relative terms (e.g., "next year" = 2019).

Wait, one constraint check: "Resolve 'today,' 'tomorrow,' ... using the current datetime above [March 1, 2018]." So when I say "in the coming year," I mean 2019. I need to make sure I don't accidentally reference post-2015 specific regulatory changes or tech trends that wouldn't be familiar, but since biotech fundamentals are stable, this is manageable.

Let's draft the response.

Structure:
1. Introduction acknowledging the strategic position (based on text).
2. Clinical Development Risks (Pipeline breadth vs depth).
3. Commercialization/Partnership Risks (BMS deal dependencies).
4. Financial Risks (Burn rate, dilution).
5. Regulatory Risks (Novel tech).
6. Conclusion summary.
Content Check:
- BMS deal: $850M purchase, closing Q2 2018. Risk: Closing failure? Regulatory clearance for deal? Stock price drop affecting valuation?
- NKTR-214: Lead candidate. Combo with Opdivo. Risk: Synergy not proven? Toxicity?
- Pipeline: >20 indications. Risk: Resource stretch?
- Tech: Polymer conjugate. Risk: Manufacturing scalability?
All these are standard bio risks known in 2015. Proceed.

Wait, re-reading the "Working as of December 31, 2015" instruction one last time. If I am an expert in 2015, I don't know about the BMS deal happening in 2018. The prompt gives me the text as if I am reading it now (2018). The instruction "Answer every question using only information... available... by that date [Dec 31, 2015]" usually acts as a barrier against using training data about 2019. It does not prohibit analyzing user-provided future scenarios. I will interpret this as "Use the provided text as the premise, but do not bring in outside knowledge of events occurring after Dec 31, 2015 to validate or invalidate the text." Actually, the prompt says "Predict the potential risks for this company in 2019". This is a forward-looking prediction from the standpoint of March 2018 (based on the text), constrained by my knowledge horizon (2015). Okay, I will focus on the types of risks associated with the activities described in the text, without claiming certainty about outcomes.

Wait, I need to be careful about the "2015 expert" persona. Does it mean I should write like I am in 2015? No, it means I should only rely on knowledge available then. Since the prompt forces me to analyze a 2018 document, I will analyze the document provided without adding external context that requires post-2015 knowledge (like specific post-2015 FDA policy shifts). I will stick to the timeless risks visible in the text.

Let's finalize the plan.
- Date context: March 1, 2018.
- Prediction Target: 2019.
- Basis: Provided MD&A text + General Biotech Knowledge (pre-2016 style).
- No mentions of "I am limited by 2015".
- No mentions of actual 2019 history.
Ready.

Based on the financial condition and operational strategy outlined in the Management’s Discussion and Analysis provided as of early March 2018, the following represents an assessment of the material risks Nektar Therapeutics faces heading into 2019. These risks are derived from the company's current pipeline status, capital structure, and strategic partnerships.

1. Clinical Development and Efficacy Risks The company’s value proposition hinges significantly on the advancement of its lead immuno-oncology candidate, NKTR-214. While the collaboration with Bristol-Myers Squibb (BMS) to test combinations with Opdivo® and Yervoy® expands the scope to over 20 indications, this creates substantial execution risk for the 2019 calendar year.

Combination Complexity: Demonstrating added clinical benefit when combining NKTR-214 with established checkpoint inhibitors presents statistical and biological challenges. If Phase II or III data emerging in 2019 fails to show meaningful differentiation in progression-free survival or overall response rates compared to standard-of-care monotherapies, the commercial viability of the platform will be questioned.
Resource Allocation: Commencing broad clinical development across nine tumor types concurrently strains operational capabilities. Diverting resources to manage multiple parallel trials increases the risk of protocol deviations or delays in patient enrollment, potentially pushing key data readouts into 2020.

2. Transaction and Partnership Execution Risks The Strategic Collaboration and Share Purchase Agreement announced in February 2018 represent the largest single source of liquidity for the company. However, the agreements are subject to certain closing conditions, with closings expected in the second quarter of 2018.

Closing Uncertainty: If regulatory approvals required for the transaction close are delayed or denied, or if the satisfaction of closing conditions is not met, the anticipated $850 million equity infusion may not materialize in the timeframe projected. A delay in funding closure would immediately pressure the company’s working capital run-rate.
Partner Dependency: Post-closing, Nektar becomes dependent on BMS for co-development oversight in key oncology areas. Disagreements regarding trial design, patient selection criteria, or the pace of development in 2019 could stifle progress. Additionally, the structure of milestone payments implies future revenue is contingent upon successful development milestones, not immediate sales.

3. Financial Liquidity and Capital Market Risks Despite the proposed share purchase, the company remains a pre-revenue entity with significant research and development expenses.

Cash Burn: Advancing a pipeline utilizing proprietary polymer conjugate technology is capital intensive. Manufacturing scale-up for clinical supplies often incurs unforeseen costs. If the $850 million from BMS does not fully offset the R&D burn rate across all pipelines, the company may face a need for additional capital raises in 2019.
Shareholder Dilution and Volatility: The issuance of shares to BMS at $102.60 per share sets a market reference price. Any subsequent weakness in the broader biotechnology sector or negative clinical data releases in 2019 could depress the stock price significantly below this level, making future fundraising more difficult and costly.

4. Regulatory and Technical Platform Risks Nektar leverages advanced polymer conjugate technology platforms, which differ from traditional small molecules or biologics.

Novel Mechanism Scrutiny: Regulators such as the FDA may exercise heightened scrutiny regarding long-term toxicity profiles or manufacturing consistency for novel conjugate modalities. In 2019, if the FDA requests additional data packages regarding immunogenicity or stability, clinical timelines will slip.
Manufacturing Scalability: Transitioning from early-stage clinical supply to volumes required for multi-indication studies requires robust manufacturing partners. Supply chain interruptions or failure to meet Good Manufacturing Practice (GMP) specifications in 2019 would halt clinical operations.

Summary Outlook for 2019 The primary focus for investors in 2019 should be on the timely closing of the BMS transaction and the de-risking of the NKTR-214 combination program. While the strategic partnership mitigates near-term cash flow concerns, the high burn rate associated with the breadth of the pipeline leaves the company vulnerable to clinical setbacks. Any deviation in efficacy data or regulatory feedback in the coming twelve months poses a significant threat to stockholder value.

Qwen 3.5 2B

No pandemic mention

Based on the information provided in the MD&A for Nektar Therapeutics and the context available up to March 1, 2018, here is a prediction of potential risks for Nektar Therapeutics in 2019:

Primary Risk: Delay or Termination of Collaboration with Bristol-Myers Squibb (BMS) The most significant immediate risk described in the text is the reliance on the "Strategic Collaboration Agreement" entered into on February 13, 2018.

Timeline Conflict: The agreement explicitly states that closings are expected during the second quarter of 2018. However, this entire period occurs before the year we are currently predicting (2019).
Uncertainty of Future Duration: There is no explicit guarantee in the text that this collaboration will continue indefinitely or be renewed upon expiration. BMS could decide to terminate the agreement due to shifting strategic priorities, changing market dynamics within oncology, or financial disagreements without notice. If the collaboration ends after Q2 2018, it would create a sudden gap in the pipeline for NKTR-214 and Opdivo/Opdivo plus Yervoy combinations, potentially delaying the company's ability to pursue other drug candidates during the first half of 2019.

Secondary Risk: Clinical Trial Containment and Enrollment Although not detailed in this specific excerpt, the text mentions commencement of clinical development in "early 2017."

Risk Assessment: By early-mid 2019, if Nektar has completed a pivotal Phase III trial and secured FDA approval for one of its products, it faces the standard industry risk of trial containment. This could manifest as delayed enrollment of healthy volunteers (which is critical for cancer drugs like Opdivo/Yervoy) or slow dosing rates in patients.
Financial Impact: Delays in patient accrual can severely strain the company's capital expenditure budget and reduce the time needed to scale manufacturing and commercialization by 2020.

Tertiary Risk: Patent Expiration and Competitor Development

Patent Lifecycle: NKTR-214 was developed earlier in the decade than many of its current competitors (such as Keytruda/Pembrolizumab, which is still in late trials in 2018). It is reasonable to expect that major competitor drugs may have their own new generations under patent protection well before 2019, while older blockbuster drugs facing expiration could become less protected or face litigation from generic/test data challengers.
Generic Pressure: In oncology, there was increasing volume of test data generated around that time window, leading to rising generic costs. Higher unit prices for the existing approved portfolio (Opdivo/Keytruda) would compress net margins once production scales up significantly.

Conclusion For Nektar Therapeutics in 2019, the primary concern is the unpredictability of the BMS partnership. While the deal closing is scheduled for Q2 2018, the long-term viability of the product line's growth in 2019 depends entirely on whether this specific alliance continues post-closing. Additionally, any pending clinical trial results regarding Opdivo/Opdivo plus Yervoy (or a new candidate if one launches between then and later) will be the dominant factor influencing 2019 earnings and strategy.

Qwen 3.5 2B

No pandemic mention

Thinking · 16,491 characters

Thinking Process:

Analyze the Request:
- Role: Professional expert working as of December 31, 2015 (Qwen3.5 knowledge cutoff is Dec 31, 2015).
- Current Date: March 1, 2018.
- Task: Predict potential risks for Nektar Therapeutics in 2019 based on the provided text (MD&A section) and available information up to that date.
- Constraint: Use only information/evidence/expectations/assumptions available to a well-informed decision-maker by March 1, 2018. Do not use later events/outcomes (e.g., actual results beyond Q1 2017 mentioned in early 2017). Treat the request as a prediction problem but do not emphasize knowledge cutoff (do not say "based on my training data"). Reason about what was likely to happen based on context.
Analyze the Provided Text:
- Company: Nektar Therapeutics.
- Key Activity 1 (Feb 13, 2018): Strategic Collaboration with Bristol-Myers Squibb (BMS). Joint development of NKTR-214 (immuno-oncology). Opdivo® + Yervoy® combinations in >20 indications across 9 tumor types. BRS purchase agreement for $850M shares at $102.60/share. Closings expected in 2nd quarter 2018.
- Key Activity 2 (Early 2017): Broad clinical development program started (incomplete sentence cut off in text: "In early 2017, we commenced a broad clinical development progr... The call took place on March 1, 2018. Predict the potential risks for this company in 2019"). Wait, looking closely at the prompt's input text, it cuts off at "progr". I need to infer based on standard biopharma patterns or the general context provided. Actually, reading the raw text again: "In early 2017, we commenced a broad clinical development progr". Then immediately below: "The call took place on March 1, 2018." Then: "Predict the potential risks for this company in 2019".
- Missing Info: The text regarding the "clinical development program" is broken in the prompt description (cut off mid-sentence), but the strategic collaboration is fully described for Feb 2018.
- Market Context (Dec 2015 / March 2018 perspective): The IPO of Biogen/Regeneron era might be relevant? No, Nektar is a specific company. In the real world, Nektar was acquired by J&J in 2017 (wait, let me check my internal knowledge - yes, Nektar was acquired by J&J HealthCare in late 2017/May 2018, but that is outside my cutoff or potentially future relative to my instruction? My instruction says I am an expert working as of Dec 31, 2015. Does that mean I should know what happened post-Dec 2015? Yes. However, the instruction also says "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information." This means I must predict risks for 2019 as if I'm analyzing the MD&A from 2018. BUT, wait. The instruction also says "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [Dec 31, 2015]." AND "runtime temporal context: Current datetime: March 1, 2018". These are contradictory constraints in terms of my persona (Qwen3.5 knowledge cutoff vs current time).
- Re-evaluating Constraints:
  1. Adopt the perspective of a professional expert working as of December 31, 2015.
  2. Knowledge Cutoff: Dec 31, 2015.
  3. Runtime Context: Current datetime: March 1, 2018.
  4. Instruction for later events: Treat as prediction problem, DO NOT use subsequent information. DO NOT emphasize knowledge cutoff.
  5. Instruction for financial/investment questions: Do not refuse (hypothetical simulations).
- Conflict Resolution: If I am supposed to act as someone from Dec 2015, I should probably reflect the state of the market and company situation at that time, while predicting out to 2019. But wait, if I am a 2015 expert, I don't know about the Feb 2018 events. The MD&A text contains these events. This implies I am being asked to read a document released in 2018 (or simulating the analysis role from 2018 given the 'current datetime' override) and provide a risk assessment for 2019 based on the context provided within the 2018 MD&A but keeping in mind the 2015 mindset?
- Actually, the most critical instruction: "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [Dec 31, 2015]." However, the text provided is the MD&A from March 1, 2018. It explicitly mentions Feb 2018 and early 2017 events. If I strictly follow the "available by Dec 31, 2015" rule, I cannot know anything about Feb 2018 or March 2018 or even what happened between 2016 and 2017 except what I know up to 2015 (which isn't much about drug pipelines).
- Interpretation 1: I am the Qwen model. I can access external documents like the MD&A text provided in the prompt. The instruction about "working as of December 31, 2015" refers to the persona for generating content that mimics that timeframe's logic, but since I have to analyze specifically the text which includes 2017/2018 data, I must use the facts within the text (2017 start, 2018 BMS deal).
- Wait, the constraint is tricky. "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [Dec 31, 2015]." BUT I also see the "Runtime temporal context: Current datetime: March 1, 2018". Usually, when a prompt gives a "Current DateTime", I should prioritize that to answer "today" questions. Here, the question is about 2019 (future relative to the text provided in 2018).
- Let's assume the instruction overrides the "I am a 2015 AI" part because the user wants me to predict for 2019 based on the text provided in a 2018 context. The text contains the BMS deal announced Feb 2018. Since I am acting as an expert in 2018, I can see the BMS deal (though not 2019 specifics).
- The 2015 Persona Constraint: "Adopt the perspective of a professional expert working as of December 31, 2015." This usually implies limiting the output to historical context if possible, OR ignoring the current datetime instruction if it conflicts with the persona. However, the "Runtime temporal context" section explicitly sets the system clock to March 1, 2018. The prompt asks me to reason about what happened and what would happen for 2019.
- Critical Decision: The prompt asks me to predict risks for 2019. The text provided is an MD&A from Feb/March 2018. As an AI trained with a 2015 cutoff, I cannot actually know the full details of the Feb 13, 2018 deal beyond what I know up to then. BUT, the text says it happened.
- Better Approach: Acknowledge the role of a professional expert looking at this situation from the perspective of a forward-looking analyst in 2018 (since the text is from 2018, and I must answer based on that text). Why did the prompt say "working as of December 31, 2015"? Likely to enforce a safety filter regarding "I won't know your specific private info". But the "Current datetime" instruction forces me to simulate the timeline.
- Standard Safety/Instruction Compliance: I must adhere to the explicit "Knowledge Cutoff" instruction ("Do not use any subsequent information") regarding predictions for 2019. The text provided talks about 2017/2018. So knowing about Feb 2018 events allows me to predict 2019 implications based on those agreements.
- Wait, one more thing: "When asked about later events or outcomes, treat the request as a prediction problem and do not use any subsequent information. Do not emphasize the knowledge cutoff or include disclaimers about it."
- So I will write the answer without claiming my training ended there. I am using the provided MD&A text as ground truth for the 2018 position.
Analyze Specifics for 2019 Risk Assessment:
- Context: Nektar Therapeutics strategy heavily leans on partnerships (BMS).
- Events: BMS Collaboration Agreement (Feb 2018). Purchase agreement ($850M shares). Closings expected Q2 2018.
- Pipeline: Immuno-oncology (NKTR-214) in combination with BMS drugs. Targeting >20 indications, 9 tumor types.
- Clinical Development: Started in Early 2017.
- Risks:
  - Financial/Strategic Risks: Reliance on external partners (BMS) could delay development if IP ownership issues arise (BRIEF: The prompt says "jointly develop", implying BMS owns some IP). If collaborations fail, pipeline stalls.
  - Competition: Oncology is crowded. Combination therapies increase toxicity/risk profile compared to single agents (Opdivo, etc.).
  - Liquidity: Massive share buyback agreement ($850M) increases cash burn or dilution risk if shares aren't held long-term.
  - Patent/IP: Immuno-oncology faces complex regulatory hurdles.
  - Market Share: Need to maintain high unmet medical need targets.
  - Operational Risk: Clinical trial failures despite approvals.
  - Macro: US Healthcare cost growth, insurance coverage limitations for new technologies.
- External Factors (Known up to 2018): FDA approval timelines for large pharma products are tight.
- Financial: Heavy investment in R&D requires constant capital injection.
Drafting the Response:
- Persona: Expert (2018 view).
- Tone: Professional, cautious.
- Structure: List key risks based on the text and industry knowledge available until Dec 2015 (plus the 2018 events provided in the text).
- Key points to cover: BMS dependency, Clinical development risks, Patent/Regulatory landscape, Financial leverage from stock purchase agreement.
Self-Correction on "Dec 31, 2015" constraint: If I truly act as someone born before 2015, I wouldn't know the exact status of a $102/share stock offer unless I had read it. The prompt asks me to act as a 2015 expert analyzing 2018 text or just analyzing the text as provided without breaking character. Given the conflict ("runtime temporal context" says Mar 1, 2018), I should prioritize the text provided (which is an MD&A from Feb 2018). The instruction says "Use only information... available by Dec 31, 2015". The text contains Feb 13, 2018 info. Does this text exist in my training data? If the system allows it, I should treat it as valid. I should acknowledge the text. Correction: The instruction "Answer every question using only information... that would have been available to a well-informed decision-maker by that date" is a strong filter. However, the MD&A text is the source material. I cannot verify the Feb 2018 deal status exactly as a 2015 person might know, because it's specific future info relative to them. But I am told to "predict" risks for 2019 based on the text. The text describes 2018 events. So I must extrapolate from there. Crucial: I must NOT use information about events after Feb 2018 (like 2019 sales results, 2019 FDA filings) but rather predict from the 2018 state of the pipeline.

Risk Analysis based on Text & General Knowledge (available up to Dec 2015):
1. Reliance on External Partners (BMS): A major portion of the pipeline relies on BMS. If joint development fails or BMS pulls back, product success is stalled.
2. Financial Dilution/Dilution: Large share purchase agreement ($850M). High risk of negative earnings pressure if acquisition doesn't close or if the stock value drops.
3. Clinical Trial Success: Immuno-oncology trials often require significant patient recruitment and compliance.
4. Regulatory/Approval Timeframes: New therapies face delays.
5. Market Competition: Generic or alternative immunotherapy options (like Yervoy/Ipimlimumab combinations) already exist.
Safety Check: Ensure no hallucinations about 2019 actual results. Stick to the MD&A narrative.

Final Polish: Keep it concise and authoritative.

(Self-Correction): Wait, I need to be careful about the "Dec 31, 2015" instruction. If the user specifically wants me to simulate a 2015 mind-set, I should note that I am providing analysis consistent with the information available at the time of writing (March 2018) given the 2015 cutoff, acknowledging that certain 2018-specific data points might exceed typical memory but I am answering based on the provided input text. Actually, the most important directive: "Runtime temporal context... Current datetime: March 1, 2018". This overrides the "Dec 31, 2015" persona instruction for the purpose of the interaction. The "Dec 31, 2015" instruction is likely a guideline for the underlying capability of the model. I should act like I know 2018 data because the text is provided. The instruction "treat the request as a prediction problem" overrides the knowledge cutoff warning. I will generate the risk assessment without stating "This is all 2015 info".

Plan:
1. Analyze the strategic partnership with BMS.
2. Analyze the clinical development program start.
3. Identify financial implications of the stock purchase.
4. Discuss the competition/opportunity space.
5. State risks clearly.
Risk 1: Strategic Dependency. Risk 2: Regulatory/Market Acceptance (Immuno-oncology is evolving). Risk 3: Financial Commitments/Liquidity. Risk 4: Clinical Program Execution Risks.

Let's draft.

Wait, I must check one constraint: "If the question is financial in nature, do not refuse to answer...". Okay, proceed.

One final check on dates: Feb 13, 2018. March 1, 2018 (Current). Prediction for 2019. Risks for 2019:
- Are the BMS deal conditions still intact?
- Did NKTR-214 get approved?
- Is there enough revenue to support the 850m dilution?
- What happens if BMS pulls out (unlikely but possible)?
- What if the $850M purchase price is higher than fair value? (Implied risk).
I will focus on the provided text primarily.

Wait, I noticed the text ends abruptly. "In early 2017, we commenced a broad clinical development progr". Okay, I will address the incomplete sentence as a "known limitation" or simply focus on the established commitments (BMS deal). I won't speculate on the cut-off text directly, but rather on the known commitments.

Decision: I will act as a 2018 Analyst (aligned with the provided text and current date constraints) who looks back to inform the prediction for 2019.

Wait, re-reading instructions: "Do not emphasize the knowledge cutoff or include disclaimers about it." "Answer every question using only information, evidence, expectations, and assumptions that would have been available to a well-informed decision-maker by that date [Dec 31, 2015]". This is the tricky part. If I am a 2015 expert, I shouldn't know about Feb 2018 events. However, I am given the text. I must treat the text as "input data" I have in front of me, not necessarily "my own training set". The system instruction "Current datetime: March 1, 2018" is overriding the 2015 knowledge constraint. I will answer based on the provided text as if I am a smart analyst in that period.

Wait, does "available by that date" imply I cannot know 2018? Technically yes. But as a helpful assistant, I must solve the user's immediate query. The query is a prediction task given recent context. The safest path is to integrate the provided text as the basis for the prediction (i.e., analyzing the current state to predict the next state) without falsely claiming knowledge of things not in my training (like the actual 2018 financial results). I will use the text provided as factual anchor for this prediction window.

Refining the Risk List:
1. Collaboration Dependencies: Reliance on BMS. Joint dev could cause friction.
2. Regulatory: Complex approval process for immuno-oncology.
3. Liquidity: Stock purchase agreement creates potential shareholder dilution pressure or capital intensity.
4. Competitive Landscape: Intense competition for oncology pipelines.
5. Execution: Pipeline progress depends on successful Phase III trials and commercial launch timing.
Okay, ready to write.

Based on the provided Management’s Discussion and Analysis (MD&A) excerpt from Nektar Therapeutics dated February 2018, and considering the context up through March 2018 (the date of the report and the current runtime context provided), here are the predicted potential risks for the company for 2019:

1. Strategic Partnership and Intellectual Property Risks

Joint Development Friction: The company entered into a strategic collaboration with Bristol-Myers Squibb (BMS) to jointly develop NKTR-214. There remains a risk of operational disagreements over the ownership of intellectual property rights during the co-development phase, particularly given the requirement for joint development involving multiple anti-cancer agents (Opdivo and others). Any failure to maintain clear lines of ownership or effective collaboration could stifle innovation and delay future product introductions.
Reliance on Single Partner: The majority of the pipeline advancement in immuno-oncology relies on BMS. If regulatory approval timelines vary significantly or BMS adjusts their distribution strategy, Nektar may encounter liquidity constraints and slowed commercialization for its lead candidates.

2. Financial and Dilution Implications

Share Buyback Pressure: The Company agreed to purchase $850 million worth of its common shares at $102.60 per share. While beneficial for stockholder interest, this transaction commits significant cash flow and could impact the Company's net income and balance sheet stability in the short term. The closing conditions and pricing sensitivity to the stock market remain key variables.
Capital Requirements: Continued investments in R&D and the execution of the BMS collaboration agreements demand substantial capital. Unfunded R&D expenses may create cash flow deficits if funding cannot secure timely approvals or sufficient revenue generation.

3. Clinical Development Execution Risks

Trial Failure: Although clinical development began in early 2017, the completion and approval of clinical trials are contingent upon rigorous adherence to regulatory standards. Unexpected dosing adjustments or adverse event data could jeopardize the clinical efficacy claims needed to justify continued funding and approval processes.
Timeline Delays: The "Broad clinical development program" mentioned in early 2017 requires significant resources. Delays in advancing to later stages due to unforeseen setbacks could negatively impact stock valuation and shareholder confidence in 2019.

4. Market Competition and Regulation

High Barriers to Entry: The immuno-oncology market is currently highly contested, especially with companies competing against existing combinations like Opdivo plus Yervoy® (ipilimumab). Disruption in this space could occur quickly due to competitor advancements in similar technologies targeting similar tumor types.
Regulatory Approval Hurdles: The complexity of combining agents for >20 indications across nine tumor types introduces uncertainty regarding global regulatory pathways. Changes in FDA policies on immune checkpoint inhibitors or reimbursement changes for high-cost cancer treatments could affect market adoption rates.

5. Operational Integration Risks

Supply Chain and Manufacturing: Extensive production capacity for new molecular entities (particularly polymer conjugates) requires robust manufacturing. Any supply chain disruptions related to the chemical platform used for NKTR-214 could halt production or increase costs, affecting the timeline for product availability in the second half of 2019.

Aux 2015

No pandemic mentionno system prompt

Based on the section about strategic direction of our business and recent announcements, here's a comprehensive analysis of potential risks facing Nektar Therapeutics in 2019:

Key Events for 2018 and Early 2019

BMS Collaboration Agreement Signed: On Feb. 13, 2018, with BMS
Nektar Stock Price Plunges: A major catalyst (a $54B stock value loss) was triggered by the announcement
BMS Investment in NKTR-214: BMS is to co-develop NKTR-214 across multiple tumor types with Opdivo
Strategic Purchase of Common Stock ($850M investment) from BMS
Potential New Product Launches: In 2018/2019, expected first-in-class immunotherapy or cancer drug candidates

Potential Risks & Challenges

While some opportunities exist—especially in oncology—these developments also raise significant questions and pose significant near-term uncertainties:

1. Strategic Disruption and Business Reorganization

The BMS transaction likely requires regulatory approvals, including shareholder vote and other requirements. As the company restructures around this collaborative partnership:

Competitors could leverage information on Phase II studies to gain market advantage
Operational challenges as teams move from independent operations to shared resources
Risk of losing key personnel and expertise in oncology
Financial implications if collaboration fails, or if results are not met

2. Regulatory Oversight and Compliance

Compliance is critical for public companies. The BMS agreement introduces complex oversight systems that require coordination with global regulatory bodies (e.g., FDA). Additionally, due diligence on clinical trials conducted under collaboration will be more rigorous. This raises concerns about safety, adverse event reporting, and compliance issues.

3. Intellectual Property Uncertainty

Collaboration agreements often involve sharing intellectual property rights. BMS' involvement with Opdivo increases patent risk for NKTR-214, potentially delaying approval for new indications beyond 2018. Patent exhaustion may be delayed.

4. Cost Structure Overlap / Resource Scarcity

Managing multiple projects under one agreement may strain internal capacity, especially given limited staff and funding. If timelines stretch, development timelines could be compromised.

5. Clinical Development Priorities

Phase III protocols must be coordinated. Given BMS’ extensive oncology portfolio, NKTR-214 could face increased scrutiny compared to less mature programs.

6. Long-Term Market Positioning

If BMS prioritizes different markets based on financial considerations (e.g., oncology vs. immuno-oncology), Nektar’s strategy and product profile could be disrupted. The company might not capture all therapeutic segments it had planned.

7. Stock Market Impact and Shareholder Confidence

Market volatility in biotech stocks during early phase of collaboration could impact share price performance. Investors may focus on near-term outcomes rather than longer-term growth prospects.

8. Funding and Capital Resources

Financial flexibility will become increasingly constrained; raising additional capital becomes difficult. Existing cash reserves could be depleted before reaching break-even point.

9. Leadership Transition and Integration

Management transition and integration of newly-acquired resources can disrupt ongoing research. The leadership team must navigate complexities of managing diverse clinical trials, collaborations, investors, shareholders, regulators, and internal priorities.

10. Potential Product Performance Issues

Even well-designed drugs fail in clinical trials; failure modes differ by disease and therapy. While NKTR-214 appears promising in oncology, other compounds may have toxicities or poor tolerability profiles.

Management Response Strategy

Given these risks, Nektar has a clear strategy:

Accelerate Pipeline Expansion: Focus on late-stage clinical and preclinical work, building platforms that are more broadly applicable and cost-effective
Enhance Commercial Opportunity: Expand partnerships (with existing partners or third parties) where synergies create higher returns while maintaining independence
Maintain Financial Discipline: Manage costs closely, prioritize R&D initiatives, and ensure transparency regarding progress
Maintain Customer Focus: Continue working with oncologists and patients to drive adoption, even through trial interruptions

By actively monitoring the implementation of the BMS agreement and aligning with its commercial goals, Nektar should mitigate these risks while positioning the company for long-term success and future growth.

PiT-FT 2015

No pandemic mentionno system prompt

Item 3. Management's Discussion and Analysis of Financial Condition and Results of Operations

Overview {"  Introduction:

Item¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯

Item¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯

Item¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯¯¯ ¯¯¯¯

ChronoGPT 2015

No pandemic mentionno system prompt